

Summary Report of Consolidated Financial Results

For the Three Months Period ended June 30, 2013



August 12, 2013
TSE/OSE-1st section

Company name: NIPRO CORPORATION

Code No.8086

URL: <http://www.nipro.co.jp/>

Representative: Yoshihiko Sano, President and Representative Director

Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division

TEL: (06)6372-2331

Filing date of quarterly reporting: August 14, 2012

Payment date of cash dividends: -

Supplemental material on quarterly reporting: No

Presentation on quarterly results: No

(Note: Amounts are truncated to one million yen)

1. Consolidated Results for the Three Months ended June 30, 2013 (From April 1, 2013 to June 30, 2013)

(1) Consolidated Results of Operations (Note: % of change from the same period a year ago)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
3 months ended June 30, 2013	70,093	19.8	2,534	(27.0)	4,322	39.7	2,441	68.9
3 months ended June 30, 2012	58,532	19.1	3,473	0.4	3,092	21.8	1,445	393.9

Note: Comprehensive income 3 months ended June 30, 2013: 24,354 million yen (-%) 3 months ended June 30, 2012: (2,781) million yen (-%)

	Earnings per share		Diluted Earnings per share	
	Yen		Yen	
3 months ended June 30, 2013	14.31		12.92	
3 months ended June 30, 2012	8.48		7.65	

(2) Consolidated Financial Position

	Total Assets		Net Assets		Equity Ratio	
	Millions of yen		Millions of yen		%	
3 months ended June 30, 2013	599,115		150,289		23.5	
Year ended March 31, 2013	579,302		128,763		20.7	

Note: Equity 3 months ended June 30, 2013: 141,067 million yen Year ended March 31, 2013: 119,973 million yen

2. Dividends

	Annual Dividends per Year				
	First-quarter	Second-quarter	Third-quarter	Year-end Dividends	Annual Dividends
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2013	-	12.00	-	15.50	27.50
Year ending March 31, 2014	-				
Year ending March 31, 2014 (Forecast)		11.00	-	14.50	25.50

Note: Revisions to the forecast of cash dividends in the current quarter: No

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2014 (From April 1, 2013 to March 31, 2014)

(Note: The % displays in the line of six months ending Sept. 30, 2013 show increase/decrease ratio against the six months ended Sept. 30, 2012. The % displays in the line of year ending March 31, 2014 show increase/decrease ratio against the year ended March 31, 2013)

	Net Sales		Operating Income		Ordinary Income		Net Income		Earnings per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
6 months ending Sept. 30, 2013	139,000	18.5	7,300	15.8	5,900	21.8	2,500	(62.2)	14.66
Year ending March 31, 2014	290,000	20.3	15,400	35.4	13,300	(7.4)	5,200	(49.2)	30.49

Note: Revisions to the forecast of consolidated financial results in the current quarter: No

*Notes

- (1) Change in Significant Subsidiaries during the Current Period
 (Change in specified subsidiaries caused a change in the scope of consolidation): No
 Additional: 0 Removal: 0
- (2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No
- (3) Change in Accounting Policies and Accounting Estimate and Restatement

[1] Changes in accounting policies by a newly issued accounting pronouncement	: No
[2] Changes other than [1]	: No
[3] Change in accounting estimate	: No
[4] Restatement	: No
- (4) Issued Shares (Common stock)

[1] Number of issued shares at end of the period (including treasury stock):	
3 months ended June 30, 2013: 171,459,479 shares	Year ended March 31, 2013: 171,459,479 shares
[2] Number of treasury stock at end of the period:	
3 months ended June 30, 2013: 908,315 shares	Year ended March 31, 2013: 914,107 shares
[3] Average number of shares during the period:	
3 months ended June 30, 2013: 170,547,387 shares	3 months ended June 30, 2012: 170,545,837 shares

*Information regarding the quarterly review procedure

This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.

*Disclaimer regarding projection information including appropriate use of forecasted financial result, and other special notes

The projection figures shown above are based on information that was available at the time of preparation and may contain certain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found in P.4 “1. Qualitative Information for the Three-Month Period Ended June 30, 2013, (3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1. Qualitative Information for the Three-Months Period ended June 30, 2013.....	2
(1) Commentary on Business Results.....	2
(2) Analysis Concerning Financial Position.....	4
(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results.....	4
2. Summary (Other) Information.....	4
(1) Changes in Significant Consolidated Subsidiaries.....	4
(2) Accounting Treatments Simplified or Unique for Preparation.....	4
(3) Changes in Accounting Policies and Accounting Estimate and Restatement.....	4
3. Consolidated Financial Statements.....	5
(1) Quarterly Consolidated Balance Sheets.....	5
(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income.....	7
Quarterly Consolidated Statements of Income.....	7
Quarterly Consolidated Statements of Comprehensive Income.....	7
(3) Notes Regarding Consolidated Financial Statement.....	8
Notes regarding going concern.....	8
Notes regarding significant changes in the amount of shareholders' equity.....	8
Segment Information.....	8
Significant Subsequent Events.....	10

1. Qualitative Information for the Three-Month Period Ended June 30, 2013

(1) Commentary on Business Results

During the current quarter period under review, the global economy generally remained in a mixed situation in which the American economy grew steadily while the credit contraction in Europe, triggered by the debt crisis there, continued.

The Japanese economy, on the other hand, has been back on the recovery path with exports picking up thanks to the ongoing yen depreciation and consumer spending remaining solid backed by rising stock prices. The overall management environment, however, remained in a harsh condition.

Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to expand sales and reduce costs.

As a result, consolidated sales for the three-month period ended June 30, 2013 increased by 19.8% from the same period of the previous year to 70,093 million yen. As for the profit, consolidated operating income decreased by 27.0% from the same period of the previous year to 2,534 million yen due to an increase in selling, general and administrative expenses. Consolidated ordinary income, however, increased by 39.7% from the same period of the previous year to 4,322 million yen thanks to the foreign exchange gains and other factors, and consolidated net income increased by 68.9% from the same period of the previous year to 2,441 million yen.

The overview of the results for the current quarter period under review by business segment is as follows.

Effective from the current quarter period under review, the pharmaceutical product sales unit of Nipro Pharma Corporation has been integrated into the Company's Domestic Division. In accordance with this change, the sales unit of Nipro Pharma Corporation, which had previously been categorized into the Pharmaceutical-Related segment, is reclassified to the Medical-Related segment. The year-on-year comparison, however, is not available for the current quarter period under review, because it is difficult to compare between figures for the segments before and after the reclassification.

(i) Medical-Related Business

Looking at the domestic market, a growth opportunity for the Group is increasing amid the ongoing growth strategy of the current government. The cabinet approved a revision of the Pharmaceutical Affairs Act to simplify and speed up the approval process of medical equipment by expanding the scope of product certification conducted by private organizations.

In addition, the pharmaceutical product sales unit of Nipro Pharma Corporation has been integrated into that of Nipro Corporation on April 1, 2013. This initiative has synergistically improved the sales capability of the Group as a comprehensive medical company that rests on medical devices (by Medical Sales Division) and pharmaceutical products (by Pharmaceutical Sales Division), and has also enabled the Group to offer a broader range of products and services more promptly through customer-oriented efforts.

Under such circumstances, sales and profits for the Medical Sales Division from the "HeartMate II (implantable ventricular assisting device)," launched in April, and the existing cardiovascular (CVS)-related products such as "extracorporeal ventricular assist devices" increased significantly. Sales were also strong in the fields such as dialysis-related products, dialysis pharmaceuticals, injection-transfusion-related products, enteral-alimentation-related products, testing-related products and vascular-related products.

Overseas sales, on the other hand, were robust because export profitability improved significantly thanks to the depreciation of the yen against the US dollar and Euro during the year. In addition, sales increased significantly from the same period of the previous year owing to our continued active efforts to enhance and expand our sales network.

By product, we have enhanced the dialysis-related product line, and consequently, sales of the related products such as artificial kidney (dialyzers), dialysis machines and indwelling needles showed a strong increase. Regarding new overseas plants, the construction of the plant in India completed at the end of the previous fiscal year, and dialysis-related products such as dialyzers, needles and syringes showed a steady increase in sales in the Indian market. A production system has been established at the Indonesian plant as well and sales grew steadily there. At the Hefei plant in China, preparations

for starting operation have progressed smoothly aiming at operation commencement at the earliest possible time.

In the current fiscal year as well, we continue to strive for sales expansion in the fast growing developing countries, while promoting community-based sales activities.

As a result, net sales of this business were 56,764 million yen.

(ii) Pharmaceutical-Related Business

The Pharmaceutical-Related Business is roughly classified into two divisions: the Generic Drugs Division, providing stable supply of high quality and low cost drugs, and the Contracted Manufacturing Division, offering high value-added products to meet customer needs for various types of drugs.

The market for the Generic Drugs Division is expected to expand further due in part to a government policy to promote generic drugs; manufactures of original drugs running sideline businesses and foreign generic manufactures have emerged, making the competitive environment of the domestic market severer.

Under such circumstances, we have worked to expand our market shares of drugs for oral or external use through cooperation with drug wholesalers, while strengthening the sales promotion to prescribing hospitals and dispensing pharmacies. In the market for large hospitals, at the same time, we have enhanced information provision activities of products such as injections. As a result, sales of this division increased steadily.

The Contracted Manufacturing Division, on the other hand, have promoted diligent marketing activities through providing various services such as contracted development and support for value adding initiatives, in addition to promoting conventional contracted manufacturing. During the current quarter period under review, sales of this division increased from the same period of the previous year because we started shipping biopharmaceuticals and major generic drugs. Furthermore, we have worked to expand contracted manufacturing through joint development with generic drug sales division and new drug development division of domestic and foreign major pharmaceutical manufactures.

Sales of pharmaceutical containers, medical-preparation- and administration-related devices were strong because we have made efforts to provide containers and systems suitable for each pharmaceutical product, focusing on various needs arising from the medical front, such as small volume bags for antimicrobial agents or osteoporosis drugs, materials for pre-filled syringes, etc., on top of rubber stoppers for pharmaceutical and vaccine use and containers for kit products. These containers and systems were developed by the Group or through joint development with pharmaceutical manufactures based on our original processing technologies for plastics, rubbers, and metals. Furthermore, under the government's policy to curb medical expenses, we have continued to work together with domestic and foreign pharmaceutical manufactures in enhancing comprehensive lifecycle management of pharmaceutical products, focusing on the development of combination products, self-injection systems, and dosage form modification in the future.

As a result, net sales of this business were 12,070 million yen.

(iii) Glass-Related Business

Sales of tube glass for ampoules were flat compared to the same period of the previous year thanks to an increase in one-off orders enjoyed during the current quarter period under review, although downward trend in domestic demand continued. Sales of tube glass for vials, on the other hand, increased from the same period of the previous year because sales in the domestic market grew steadily thanks to an increase in orders for vials for vaccines.

Among other glass-related products, sales of thermos bottles decreased from the same period of the previous year due to a decline in export and weak domestic demand. Regarding glass for lighting purpose, demand for automotive electric lamp products increased on the back of strong trends in the auto industry, while demand for glass products for lightning decreased being negatively affected by popularization of LEDs. Thus, although sales of tube glass for electric lamps increased slightly from the same period of the previous year, overall sales of glass for lighting purpose decreased from the same period of the previous year due to the weak trends in glass products for lighting.

As a result, net sales of this business were 1,199 million yen.

(iv) Other Business

Among other business, sales from the real-estate rental business were 58 million yen.

(2) Analysis Concerning Financial Position

Analysis Concerning the Conditions of Assets, Liabilities and Net Assets

Total assets increased by 19,812 million yen from the end of the previous year to 599,115 million yen. Current assets decreased by 8,132 million yen primarily due to a decrease of 21,043 million yen in cash and deposits, and noncurrent assets increased by 27,945 million yen primarily due to an increase of 17,473 million yen in investment securities.

Total liabilities decreased by 1,713 million yen from the end of the previous year to 448,825 million yen. Current liabilities increased by 144 million yen primarily due to an increase of 4,079 million yen in notes and accounts payable-trade, and noncurrent liabilities decreased by 1,858 million yen primarily due to a decrease of 1,658 million yen in long-term loans payable.

Total net assets increased by 21,526 million yen from the end of the previous year to 150,289 million yen. Shareholders' equity decreased by 241 million yen and accumulated other comprehensive income increased by 21,335 million yen.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

Concerning the global economy in the future, the American economy is expected to remain on a recovery path and the emerging economies are expected to recover as well, while the sluggishness of the European economy poses a downside risk to the business activities. As to the Japanese economy, an increase in resource prices including those of crude oils is of concern, and companies are taking a cautious stance toward an increase in personnel costs. Thus, the overall management environment is expected to remain in a harsh condition.

Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand sales and reduce production costs.

At this moment, we have not made any revision to the forecast of consolidated financial results for the year ending March 31, 2014, which was announced on May 14, 2013.

2. Summary (Other) Information

(1) Changes in Significant Consolidated Subsidiaries

N/A

(2) Accounting Treatments Simplified or Unique for Preparation

N/A

(3) Changes in Accounting Policies and Accounting Estimate and Restatement

N/A

3. Consolidated Financial Statements

(1) [Quarterly Consolidated Balance Sheets]

(Millions of yen)

	As of March 31, 2013	As of June 30, 2013
Assets		
Current Assets		
Cash and deposits	106,000	84,957
Notes and accounts receivable-trade	83,665	89,418
Merchandise and finished goods	53,899	55,777
Work in process	10,480	10,552
Raw materials and supplies	17,275	18,398
Deferred tax assets	5,375	4,556
Other	11,741	16,668
Allowance for doubtful accounts	(463)	(488)
Total current assets	287,974	279,841
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	138,547	149,880
Accumulated depreciation and impairment loss	(69,911)	(72,610)
Buildings and structures, net	68,636	77,270
Machinery, equipment and vehicles	170,522	176,884
Accumulated depreciation and impairment loss	(117,991)	(123,649)
Machinery equipment and vehicles, net	52,530	53,234
Land	22,173	22,490
Lease assets	3,203	3,174
Accumulated depreciation	(2,029)	(2,045)
Lease assets, net	1,174	1,129
Construction in progress	23,786	21,315
Other	33,113	34,644
Accumulated depreciation and impairment loss	(26,712)	(27,885)
Other, net	6,400	6,758
Total property, plant and equipment	174,702	182,198
Intangible assets		
Goodwill	22,740	29,681
Lease assets	567	522
Other	10,958	11,474
Total intangible assets	34,265	41,678
Investments and other assets		
Investment securities	63,141	80,614
Deferred tax assets	8,805	3,549
Other	13,767	14,648
Allowance for doubtful accounts	(3,353)	(3,416)
Total investments and other assets	82,360	65,396
Total noncurrent assets	291,328	319,273
Total assets	579,302	599,115

(Millions of yen)

	As of March 31, 2013	As of June 30, 2013
Liabilities		
Current liabilities		
Notes and accounts payable-trade	40,878	44,958
Short-term loans payable	127,238	128,269
Commercial papers	10,000	10,000
Current portion of bonds	1,277	1,252
Lease obligations	1,011	982
Accounts payable-other	8,286	6,839
Accrued directors' bounuses	316	-
Income taxes payable	4,266	2,864
Provision for bounuses	2,810	1,842
Provision for directors' bounuses	70	85
Provision for loss on business liquidation	1,954	1,954
Notes payable-facilities	3,734	1,147
Other	11,912	13,705
Total current liabilities	213,758	213,902
Noncurrent liabilities		
Bonds payable	47,147	46,855
Convertible bond-type bonds with subscription rights to shares	14,900	14,895
Long-term loans payable	164,906	163,248
Lease obligations	2,040	1,946
Deferred tax liabilities	2,212	2,282
Provision for retirement benefits	2,854	2,969
Provision for directors' retirement benefits	742	757
Provision for loss on litigation	218	218
Other	1,757	1,749
Total noncurrent liabilities	236,780	234,922
Total liabilities	450,539	448,825
Net assets		
Shareholders' equity		
Capital stock	84,397	84,397
Capital surplus	636	635
Retained earnings	54,788	54,542
Treasury stock	(865)	(859)
Total shareholders' equity	138,957	138,715
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(12,547)	(1,182)
Foreign currency translation adjustment	(6,436)	3,534
Total accumulated other comprehensive income	(18,983)	2,352
Minority interests	8,789	9,221
Total net assets	128,763	150,289

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]
 Quarterly Consolidated Statements of Income

(Amount: million yen)

	FY2012 first three months (From April 1, 2012 to June 30, 2012)	FY2013 first three months (From April 1, 2013 to June 30, 2013)
Net sales	58,532	70,093
Cost of sales	42,197	50,064
Gross profit	16,335	20,029
Selling, general and administrative expenses	12,861	17,494
Operating income	3,473	2,534
Non-operating income		
Interest income	232	221
Dividends income	860	940
Foreign exchange gain	—	1,461
Other	214	322
Total non-operating income	1,306	2,946
Non-operating expenses		
Interest expenses	845	971
Foreign exchange losses	757	—
Equity in losses of affiliates	24	—
Other	60	187
Total non-operating expenses	1,687	1,158
Ordinary income	3,092	4,322
Extraordinary income		
Gain on sales of noncurrent assets	24	199
State subsidy□	40	1
Gain on negative goodwill	39	4
Compensation income	—	570
Other	8	70
Total extraordinary income	113	846
Extraordinary loss		
Loss on retirement of noncurrent assets	21	17
Loss on reduction of noncurrent assets	29	—
Company funeral expenses	40	—
Structural integration expenses	—	30
Other	15	14
Total extraordinary losses	107	62
Income before income taxes and minority interests	3,099	5,106
Income taxes-current	1,040	2,361
Income taxes-deferred	549	261
Total income taxes	1,589	2,622
Income before minority interests	1,509	2,483
Minority interests in income	64	42
Net income	1,445	2,441

[Quarterly Consolidated Statements of Comprehensive Income]

(Amount: million yen)

	FY2012 first three months (From April 1, 2012 to June 30, 2012)	FY2013 first three months (From April 1, 2013 to June 30, 2013)
Income before minority interests	1,509	2,483
Other comprehensive income		
Valuation difference on available-for-sale securities	(10,074)	11,364
Foreign currency translation adjustment	5,783	10,506
Total other comprehensive income	(4,291)	21,871
Comprehensive income	(2,781)	24,354
Comprehensive income attributable to owners of the parent	(2,887)	23,777
Comprehensive income attributable to minority interests	106	577

(3) Notes Regarding Consolidated Financial Statement

(Notes regarding going concern)

N/A

(Notes regarding significant changes in the amount of shareholders' equity)

N/A

(Segment Information)

I FY2012 (From April 1, 2012 to June 30, 2012)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated Statements of Income (Note.3)
	Medical- Related	Pharmaceutical- Related	Glass- Related	Total				
Net sales								
(1)Sales to third parties	40,634	16,668	1,171	58,474	58	58,532	—	58,532
(2)Inter-segment sales and transfers	290	1,665	105	2,061	11	2,073	(2,073)	—
Total	40,924	18,333	1,277	60,535	69	60,605	(2,073)	58,532
Segment profit	3,664	1,657	197	5,519	54	5,574	(2,101)	3,473

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
2. Adjustment for the segment profit of (2,101) million yen includes elimination of inter-segment transaction of (251) million yen and corporate cost of (1,849) million yen. Corporate cost consisted primarily of general and administrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment

N/A

II FY2013 (From April 1, 2013 to June 30, 2013)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated Statements of Income (Note.3)
	Medical- Related	Pharmaceutical- Related	Glass- Related	Total				
Net sales								
(1)Sales to third parties	56,764	12,070	1,199	70,034	58.	70,093	—	70,093
(2)Inter-segment sales and transfers	308	1,787	136	2,233	10	2,243	(2,243)	—
Total	57,073	13,858	1,336	72,268	68	72,336	(2,243)	70,093
Segment profit	3,634	2,128	143	5,906	54	5,961	(3,426)	2,534

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
2. Adjustment for the segment profit of (3,426) million yen includes elimination of inter-segment transaction of (1,113) million yen and corporate cost of (2,313) million yen. Corporate cost consisted primarily of general and administrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments

- (1) Effective from the third quarter period ended December 31, 2012, the name of the following reportable business segment has been changed: from "Materials" to "Glass-Related."

This arrangement only involves a change in the name of the business segment, and classification has not been changed from the first quarter period ended June 30, 2012. Reflecting this change, the segment information for the first quarter period ended June 30, 2012 is presented using the revised name.

- (2) Effective from the third quarter period ended December 31, 2012, we have partially changed our organization so that we can strengthen the Pharmaceutical-Related Business further and facilitate close coordination between the Medical-Related Business and the Glass-Related Business. In accordance with this change, a part of business divisions, which had previously been categorized into the Glass-Related segment, has been reclassified to the Pharmaceutical-Related segment.

The segment information for the first quarter period ended June 30, 2012 is prepared based on the reportable segments after the reclassification.

- (3) Effective from the quarter period under review, the pharmaceutical product sales unit of Nipro Pharma Corporation has been integrated into the Company's Domestic Division so that we can enhance our management capability through close coordination between the three divisions: the Medical Devices Division, the Pharmaceutical Products Division, and the Glass and Materials Division. In accordance with this change, the sales unit, which had previously been categorized into the Pharmaceutical-Related segment, is reclassified to the Medical-Related segment.

The segment information for the first quarter period ended June 30, 2012 after reclassification, except for sales to external customers, is not available to the public, because accurately and retrospectively extracting data for cost of sales and selling, general and administrative expenses is practically difficult. In addition, the segment information for the current quarter period under review based on the segments before the reclassification is not available to the public either, because it is practically difficult to obtain necessary information to prepare it.

Sales to the external customers for the first quarter period ended June 30, 2012, if prepared based on the segments before the reclassification, would have been 45,704 million yen for the Medical-Related segment and 11,597 million yen for the Pharmaceutical-Related segment.

- (4) Effective from the current quarter period under review, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd., Jilin Nipro Jiaheng Pharmaceutical Packing Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd., which had previously been categorized into the Glass-Related segment, are reclassified to the Medical-Related segment, as a result of review and re-examination as part of our international management strategy.

The segment information for the first quarter period ended June 30, 2012 is prepared based on the reportable segment after the reclassification.

3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment

(Material Change in the Amount of Goodwill)

In the Medical-Related segment, Nichihos Co., Ltd. and its 10 subsidiary companies have been included in the scope of consolidation as a result of acquisition of their shares. As a result, unamortized balance of goodwill increased 6,851 million yen from the end of the previous period.

(Significant Subsequent Events)

Acquisition and Tender Offer of Treasury Stocks

Based on the Board of Directors meeting dated May 14, 2013, the Company acquired treasury stocks, by means of tender offer ("Tender Offer") to be specific, pursuant to the provisions of Article 156, Paragraph 1 of the Companies Act (Law No. 86 of 2005, as amended, "the Act"), applied by replacing certain terms provided pursuant to Article 165, Paragraph 3 of the Act, and the provisions of the Company's Articles of Incorporation.

1. Outline of the Tender Offer, etc.

Class of Shares:	Common Stock
Total Number of Shares:	37,721,000 shares
Purchase Price:	862 yen per common stock
Funds Required for Purchase:	32,539 million yen
Period of Tender Offer:	From May 15, 2013 (Wednesday) through June 11, 2013 (Tuesday) (20 business days in Japan)

2. Results of the Tender Offer, etc.

Number of Tendered Shares:	19,834,000 shares
Number of Shares Purchased:	19,834,000 shares
(Note) Percentage to the total shares issued:	11.57% (rounded to the two decimal points)

3. Results of the Acquisition of Treasury Stocks

Class of Shares Purchased:	Common Stock
Total Number of Shares Purchased:	19,834,000 shares
Total Acquisition Value:	17,096 million yen
(Note) Commissions to be paid to the tender offer agent and other expenses are not included in the above value.	
Date of Acquisition:	July 4, 2013